Novartis Seeks U.S. Approval for Two Smoker’s Cough Drugs
This article is for subscribers only.
Novartis AG applied for U.S. regulatory approval for two drugs to treat smoker’s cough that analysts estimate could generate an additional $1.4 billion in annual sales for the Swiss drugmaker.
Third-phase clinical tests for QVA149 and NVA237 showed “positive” results for the treatment of chronic obstructive pulmonary disorder, or smoker’s cough, Basel-based Novartis said today in a statement. The filing was made in the fourth quarter of last year, the company said.